Our data showed that dual-targeted CAR-T cells had a higher proliferation capacity in the presence of PD-L1+ tumor cells (Fig. 4b), whereas single-targeted HER2 CAR-T cells presented lower proliferation activity. This evidence concerns the gene ERBB2 and neoplasm.